Drug Trial Radar · NCT07660614
A Study of LTX-002 in Adult Participants With Amyotrophic Lateral Sclerosis
Last checked: Nov 19, 2026Latest source record: Aug 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
56
Planned (sponsor's estimate)
Start
Apr 29, 2026
Primary completion
Jun 2031
Study completion Jun 2031
Sponsor
- Lead sponsor
- Leal Therapeutics, IncIndustry
- Sponsor type
- Industry
- First posted
- Jun 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will examine what happens when patients with amyotrophic lateral sclerosis (ALS) are given an investigational medication (study drug) known as LTX-002. Specifically, the researchers will be looking at safety, tolerability (if someone has any side effects from the drug), pharmacokinetics (what the body does to the study drug) and pharmacodynamics (what the study drug does to the body). The study will also investigate the effect of the drug on indicators of the severity of ALS, such as markers in blood and in the cerebrospinal fluid (the fluid that surrounds the brain and spinal cord, CSF) and on measures of the participant's ability to move, speak, and breathe.
Conditions
- Amyotrophic Lateral Sclerosis
Interventions
LTX-002Drug
LTX-002 is an antisense oligonucleotide (ASO) targeting SPTLC1 messenger RNA (mRNA). Several dose levels will be tested.
Placebo (aCSF)Other
Sterile aCSF solution formulation intended for intrathecal administration.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and Tolerability (Adverse Events)Time frame: Screening to Day 169
- Safety and Tolerability (Clinical Laboratory Tests)Time frame: Screening to Day 169
- Safety and Tolerability (Vital Signs)Time frame: Screening to Day 169
- Safety and Tolerability (Physical and Neurological exams)Time frame: Screening to Day 169
- Safety and Tolerability (ECGs - heart rate)Time frame: Screening to Day 169
- Safety and Tolerability (ECGs - QRS)Time frame: Time Frame: Screening to Day 169
- Safety and Tolerability (ECGs - QT)Time frame: Screening to Day 169
- Safety and Tolerability (ECGs - QTc)Time frame: Screening to Day 169
- Safety and Tolerability (ECGs - PR intervals)Time frame: Screening to Day 169
Locations
5 sites in 4 countries. Site status is shown where the registry gives one.
University Hospital Schleswig-Holstein, Campus Lübeck
Lübeck, Germany · Recruiting
Istituto Neurologico "Carlo Besta"
Milan, Italy · Not yet recruiting
AOU Città della Salute e della Scienza di Torino
Torino, Italy · Recruiting
Universitair Medisch Centrum Utrecht
Utrecht, Netherlands · Recruiting
Karolinska Universitetssjukhuset
Stockholm, Sweden · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.